Literature DB >> 27925284

Extent of agreement between the body fluid model of Sysmex XN-20 and the manual microscopy method.

Wei-Hua Huang1, Lin-Peng Lu2, Kang Wu1, Fang-Yu Guo1, Jie Guo1, Jing-Long Yu1, Dao-Yin Zhou1, Yi Sun1, An-Mei Deng3.   

Abstract

BACKGROUND: Although the correlations concerning cellular component analysis between the Sysmex XN-20 body fluid (BF) model and manual microscopy have been investigated by several studies, the extent of agreement between these two methods has not been investigated.
METHODS: A total of 90 BF samples were prospectively collected and analyzed using the Sysmex XN-20 BF model and microscopy. The extent of agreement between these two methods was evaluated using the Bland-Altman approach. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic accuracy of high-fluorescence (HF) BF cells for malignant diseases.
RESULTS: The agreements of white blood cell (WBC), red blood cell (RBC), and percentages of neutrophils, lymphocytes, and monocytes between the Sysmex XN-20 BF model and manual microscopy were imperfect. The areas under the ROC curves for absolute and relative HF cells were 0.67 (95% confidence interval [CI]: 0.56-0.78) and 0.60 (95% CI: 0.48-0.72), respectively.
CONCLUSION: Due to the Sysmex XN-20 BF model's imperfect agreement with manual microscopy and its weak diagnostic accuracy for malignant diseases, the current evidence does not support replacing manual microscopy with this model in clinical practice.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Bland-Altman approach; SysmexXN-20; agreement; cellular component analysis; high-fluorescence cell

Mesh:

Year:  2016        PMID: 27925284      PMCID: PMC6816966          DOI: 10.1002/jcla.22101

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  10 in total

1.  An evaluation of the utility of performing body fluid counts on the coulter LH 750.

Authors:  P W Barnes; C S Eby; G Shimer
Journal:  Lab Hematol       Date:  2004

Review 2.  Body fluid analysis: clinical utility and applicability of published studies to guide interpretation of today's laboratory testing in serous fluids.

Authors:  Darci R Block; Alicia Algeciras-Schimnich
Journal:  Crit Rev Clin Lab Sci       Date:  2013 Jul-Oct       Impact factor: 6.250

Review 3.  Body fluid biomarkers in Alzheimer's disease.

Authors:  Huan Lu; Xi-Chen Zhu; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-04

4.  Detection of malignant cells in serous body fluids by counting high-fluorescent cells on the Sysmex XN-2000 hematology analyzer.

Authors:  D Labaere; N Boeckx; I Geerts; M Moens; M Van den Driessche
Journal:  Int J Lab Hematol       Date:  2015-06-13       Impact factor: 2.877

Review 5.  Body fluid cell counts by automated methods.

Authors:  Linda M Sandhaus
Journal:  Clin Lab Med       Date:  2014-12-04       Impact factor: 1.935

6.  Validation of the body fluid module on the new Sysmex XN-1000 for counting blood cells in cerebrospinal fluid and other body fluids.

Authors:  Chérina Fleming; Rob Brouwer; Jan Lindemans; Robert de Jonge
Journal:  Clin Chem Lab Med       Date:  2012-10-01       Impact factor: 3.694

7.  Limits of agreement (Bland-Altman method).

Authors:  Philip Sedgwick
Journal:  BMJ       Date:  2013-03-15

8.  Body fluid cellular analysis using the Sysmex XN-2000 automatic hematology analyzer: focusing on malignant samples.

Authors:  Y-U Cho; H-S Chi; S H Park; S Jang; Y-J Kim; C-J Park
Journal:  Int J Lab Hematol       Date:  2014-09-12       Impact factor: 2.877

9.  Performance evaluation of the new hematology analyzer Sysmex XN-series.

Authors:  J Y Seo; S-T Lee; S-H Kim
Journal:  Int J Lab Hematol       Date:  2014-05-12       Impact factor: 2.877

10.  Performance evaluation of the body fluid mode on the platform Sysmex XE-5000 series automated hematology analyzer.

Authors:  A Paris; T Nhan; E Cornet; J-P Perol; M Malet; X Troussard
Journal:  Int J Lab Hematol       Date:  2010-03-03       Impact factor: 2.877

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.